MA-ONPROCESS-TECHNOLOGY
30.9.2021 13:02:11 CEST | Business Wire | Press release
OnProcess Technology, Inc. , a global pioneer powering the world’s circular service supply chains, announced today the general availability of its new cloud-based technology platform, OnProcess Agora™ along with Agora Recover™, an asset recovery solution that delivers new levels of digital customer experience. The OnProcess Agora platform, which hosts a suite of applications, communications and business intelligence tools underpinned by a proprietary data model, helps improve the management, efficiency and orchestration at every stage of the service-parts supply chain. The solution automates key after-sales processes and equips customers with a digital-first approach that results in greater financial, sustainability and customer service outcomes.
Today’s after-sale supply chain continues to be incredibly manual, siloed and complex. This makes orchestrating a circular supply chain – where manufacturers and sellers order, consume, return and refurbish used parts to cut down on costs, reduce waste and improve service – nearly impossible. OnProcess Agora™ overcomes this challenge by integrating the entire service supply chain into a single platform and automatically capturing and blending parts data, customer data and OnProcess proprietary data across the post-sale service lifecycle.
“The after-sale service supply chain has a direct and substantial impact on customer service, sustainability outcomes and the bottom line. Unfortunately, the typical service supply chain today is a web of disconnected, manual processes managed by siloed departments and systems,” said Oliver Lemanski, CEO of OnProcess. “That’s why we designed Agora, which gives our customers complete control and visibility across the service supply chain, and uniquely combines parts management data with data that focuses on the customer experience. The platform is a key enabler of our company’s vision to power the world’s circular service supply chains and puts sustainability and customer lifetime value at the heart of the everything-as-a-service economy.”
OnProcess’ AI-driven digital solution for asset recovery, Agora Recover™ , is the first application to be released on the OnProcess Agora™ platform. With sophisticated reporting capabilities, self-service portals and cloud-based integrations into almost any application or data source, Agora Recover supports the circular service supply chain by giving customers a holistic view of the parts recovery cycle. The resulting visibility and intelligence reduce unnecessary transportation costs and promotes sustainability by intelligently redirecting recovered parts according to value, demand and reusability.
“Agora Recover makes it easier to recover the inventory that matters most and provides new digital services for a more frictionless customer experience,” added Lemanski. “By providing real-time information to the right people, when and where they need it, helps teams recover parts faster, make better decisions, optimize operations, improve warranty recovery, reduce costs and emissions, and significantly improve customer satisfaction.”
To learn more about OnProcess Agora™ or Agora Recover™, or to request a demonstration, visit www.onprocess.com .
About OnProcess Technology, Inc.
OnProcess supplies technology and services that powers the world’s circular service supply chains. Providing managed services and digital transformation expertise that streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals, OnProcess is a trusted advisor to many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005199/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
